Table 3.
Characteristics | Baseline | Two years' SLIT |
---|---|---|
IL-36γ (pg/mL) | 956.3 ± 315.2 | 413.2 ± 159.8∗ |
IL-5 (pg/mL) | 22.5 ± 8.9 | 11.3 ± 5.4∗ |
IL-13 (pg/mL) | 295.1 ± 78.5 | 75.3 ± 21.6∗ |
Proportion of ILC2 (%) | 0.13 ± 0.05 | 0.03 ± 0.01∗ |
Abbreviations: IL-5, interleukin-5; IL-13, interleukin-13; IL-36γ, interleukin-36γ; ILC2, IL-36γ on group II lymphoid cell; SLIT, sublingual immunotherapy.
∗ Compared with baseline, P < 0.05.